Literature DB >> 12366710

Expression of the bcl-2 family of pro- and anti-apoptotic genes in multiple myeloma and normal plasma cells: regulation during interleukin-6(IL-6)-induced growth and survival.

Helena Spets1, Thomas Strömberg, Patrik Georgii-Hemming, Jan Siljason, Kenneth Nilsson, Helena Jernberg-Wiklund.   

Abstract

Aberrant expression of genes regulating apoptosis/survival seems to be essential in the stepwise development of human multiple myeloma (MM). In this paper we have compared the expression of bcl-2 family pro- and anti-apoptotic genes in MM cell lines, primary MM cells and normal plasma cells. The Bcl-2, Mcl-1, Bcl-xL/S, Bcl-w, Bax, Bak, and Bad were shown to be expressed in both malignant and non-neoplastic, normal plasma cells. Quantitative analysis revealed that the malignant phenotype seemed to correlate with an elevated expression of Mcl-1, a decreased expression of Bax and, to a lesser extent, an increased Bcl-2/Bax expression ratio. The possible influence of interleukin-6 (IL-6) in regulating the expression of the bcl-2-related genes was also examined. Using the IL-6-dependent MM cell lines U-1958 and U-266-1970 it was clearly shown that IL-6 deprivation induced cell cycle arrest in both cell lines, whereas apoptosis was only detected in the U-1958 cells. Furthermore, the anti-apoptotic proteins Bcl-2, Mcl-1 and Bcl-xL were down-regulated, while the expression of the pro-apoptotic Bax protein was increased. To conclude, we suggest that the expression pattern of the Bcl-2 family of proteins separates the malignant phenotype of MM from normal plasma cells, and that the protecting effect of IL-6 may be conducted via an altered balance between these proteins.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12366710     DOI: 10.1034/j.1600-0609.2002.01549.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  31 in total

1.  IL-6/STAT3 signaling pathway is activated in plasma cell mastitis.

Authors:  Yang Liu; Jian Zhang; Yu-Hui Zhou; Yi-Na Jiang; Wei Zhang; Xiao-Jiang Tang; Yu Ren; Shui-Ping Han; Pei-Jun Liu; Jing Xu; Jian-Jun He
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

2.  CpG DNA activation and plasma-cell differentiation of CD27- naive human B cells.

Authors:  Jennifer Huggins; Tina Pellegrin; Raymond E Felgar; Chungwen Wei; Miguel Brown; Bo Zheng; Eric C B Milner; Steven H Bernstein; Ignacio Sanz; Martin S Zand
Journal:  Blood       Date:  2006-10-10       Impact factor: 22.113

3.  Gene expression of anti- and pro-apoptotic proteins in malignant and normal plasma cells.

Authors:  Michel Jourdan; Thierry Reme; Hartmut Goldschmidt; Geneviève Fiol; Véronique Pantesco; John De Vos; Jean-François Rossi; Dirk Hose; Bernard Klein
Journal:  Br J Haematol       Date:  2009-01-08       Impact factor: 6.998

4.  VEGFR2 survival and mitotic signaling depends on joint activation of associated C3ar1/C5ar1 and IL-6R-gp130.

Authors:  Ming-Shih Hwang; Michael G Strainic; Elliot Pohlmann; Haesuk Kim; Elzbieta Pluskota; Diana L Ramirez-Bergeron; Edward F Plow; M Edward Medof
Journal:  J Cell Sci       Date:  2019-03-28       Impact factor: 5.285

5.  Bortezomib-based chemotherapy regimens can improve response in newly diagnosed multiple myeloma patients with bcl-2 and survivin overexpression.

Authors:  Wen Zeng; Fankai Meng; Zeming Liu; Xia Mao; Li Luo; Miao Zheng; Shuang Qin; Wenli Liu; Jianfeng Zhou; Hanying Sun; Lifang Huang
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

6.  BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone.

Authors:  Jérôme Moreaux; Eric Legouffe; Eric Jourdan; Philippe Quittet; Thierry Rème; Cécile Lugagne; Philippe Moine; Jean-François Rossi; Bernard Klein; Karin Tarte
Journal:  Blood       Date:  2003-12-04       Impact factor: 22.113

7.  R-(-)-gossypol (AT-101) activates programmed cell death in multiple myeloma cells.

Authors:  Michael P Kline; S Vincent Rajkumar; Michael M Timm; Teresa K Kimlinger; Jessica L Haug; John A Lust; Philip R Greipp; Shaji Kumar
Journal:  Exp Hematol       Date:  2008-03-17       Impact factor: 3.084

8.  The protein tyrosine phosphatase CD45 is required for interleukin 6 signaling in U266 myeloma cells.

Authors:  Qun Zhou; Yuan Yao; Solveig G Ericson
Journal:  Int J Hematol       Date:  2004-01       Impact factor: 2.490

9.  Novel targeted deregulation of c-Myc cooperates with Bcl-X(L) to cause plasma cell neoplasms in mice.

Authors:  Wan Cheung Cheung; Joong Su Kim; Michael Linden; Liangping Peng; Brian Van Ness; Roberto D Polakiewicz; Siegfried Janz
Journal:  J Clin Invest       Date:  2004-06       Impact factor: 14.808

10.  Deregulation of c-Myc Confers distinct survival requirements for memory B cells, plasma cells, and their progenitors.

Authors:  Sefat E Khuda; William M Loo; Siegfried Janz; Brian Van Ness; Loren D Erickson
Journal:  J Immunol       Date:  2008-12-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.